Search company, investor...

Founded Year

2012

Stage

Series C | Alive

Total Raised

$66.6M

Last Raised

$30M | 1 yr ago

About Prokarium

Prokarium is a biopharmaceutical company that focuses on developing vaccination and cancer immunotherapy solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company was founded in 2012 and is based in London, U.K.

Headquarters Location

2 Royal College St London Bioscience Innovation Centre

London, England, NW1 ONH,

United Kingdom

+44 07811367729

Loading...

Prokarium's Products & Differentiators

    S. Typhi

    Salmonella Typhi ZH9

Loading...

Expert Collections containing Prokarium

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Prokarium is included in 1 Expert Collection, including Synthetic Biology.

S

Synthetic Biology

238 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Prokarium Patents

Prokarium has filed 8 patents.

The 3 most popular patent topics include:

  • immunology
  • cancer treatments
  • clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/10/2021

12/20/2022

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Cancer treatments

Grant

Application Date

6/10/2021

Grant Date

12/20/2022

Title

Related Topics

Clusters of differentiation, Immunology, Immune system, Monoclonal antibodies, Cancer treatments

Status

Grant

Latest Prokarium News

Prokarium begins clinical trial of bladder cancer immunotherapy

Feb 8, 2024

The Phase I/Ib trial aims to assess the safety of a single intravesical dose of ZH9 in on-muscle invasive bladder cancer (NMIBC) patients. February 8, 2024 The PARADIGM-1 trial will enrol patients with non-muscle invasive bladder cancer in the US. Credit: Shidlovski / Shutterstock. UK-based biopharmaceutical company Prokarium has dosed the first subject in the PARADIGM-1 Phase I/Ib study of ZH9, an investigational bacterial immunotherapy, for patients with non-muscle invasive bladder cancer (NMIBC) in the US. This development follows the clearance of an investigational new drug (IND) application by the US Food and Drug Administration (FDA) in November last year, allowing the trial commencement. Go deeper with GlobalData It aims to assess the safety of a single intravesical dose of ZH9 in NMIBC patients. The study will also analyse the clinical efficacy of ZH9 in pre-planned expansion cohorts under the same IND. See Also: How well do you really know your competitors? Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge. Not ready to buy yet? Download a free sample We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form By GlobalData Submit Tick here to opt out of curated industry news, reports, and event updates from Clinical Trials Arena. I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the privacy policy Submit and download Prokarium CMO Dr Josefin-Beate Holz said: “Dosing our first patient in the clinical trial is an exciting milestone. “It translates our scientific promises into practical advancements, as we strive to transform the treatment paradigm for patients with NMIBC.” The company’s Living Cures platform is designed to modernise precision medicine by creating programmable off-the-shelf therapeutics. This platform could lead to a new class of immunotherapies to provide equitable access. Following an announcement of its partnership with Ginkgo Bioworks in January 2023, Prokarium secured $30m in new funding in February. Prokarium CEO Kristen Albright said: “We are grateful to the patients and urologists involved in the PARADIGM-1 clinical trial. “This achievement represents a pivotal moment for Prokarium as we introduce Living Cures, a novel class of immunotherapies built with synthetic biology.” Sign up for our daily news round-up! Give your business an edge with our leading industry insights.

Prokarium Frequently Asked Questions (FAQ)

  • When was Prokarium founded?

    Prokarium was founded in 2012.

  • Where is Prokarium's headquarters?

    Prokarium's headquarters is located at 2 Royal College St, London.

  • What is Prokarium's latest funding round?

    Prokarium's latest funding round is Series C.

  • How much did Prokarium raise?

    Prokarium raised a total of $66.6M.

  • Who are the investors of Prokarium?

    Investors of Prokarium include Flerie Invest, Korea Investment Partners, Riyadh Valley Company, UK Future Fund and Wellcome Trust.

  • Who are Prokarium's competitors?

    Competitors of Prokarium include ImmunityBio.

  • What products does Prokarium offer?

    Prokarium's products include S. Typhi and 2 more.

Loading...

Compare Prokarium to Competitors

ImmunityBio Logo
ImmunityBio

ImmunityBio develops immunotherapy products and cell therapies in the healthcare and biotechnology industry. The company's main offerings include therapies designed to strengthen each patient's natural immune system, potentially enabling it to eliminate cancerous or infected cells. ImmunityBio primarily sells to the healthcare industry. ImmunityBio was formerly known as NantCell. It was founded in 2014 and is based in Culver City, California.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.